Yayın:
SARS-CoV-2 Mutations and their Viral Variants

dc.contributor.authorCosar, Begum
dc.contributor.authorKaragulleoglu, Zeynep Yagmur
dc.contributor.authorUnal, Sinan
dc.contributor.authorInce, Ahmet Turan
dc.contributor.authorUncuoglu, Dilruba Beyza
dc.contributor.authorTuncer, Gizem
dc.contributor.authorKilinc, Bugrahan Regaip
dc.contributor.authorOzkan, Yunus Emre
dc.contributor.authorOzkoc, Hikmet Ceyda
dc.contributor.authorDemir, Ibrahim Naki
dc.contributor.authorEker, Ali
dc.contributor.authorKaragoz, Feyzanur
dc.contributor.authorSimsek, Said Yasin
dc.contributor.authorYasar, Bunyamin
dc.contributor.authorPala, Mehmetcan
dc.contributor.authorDemir, Aysegul
dc.contributor.authorAtak, Irem Naz
dc.contributor.authorMendi, Aysegul Hanife
dc.contributor.authorBengi, Vehdi Umut
dc.contributor.authorSevel, Guldane Cengiz
dc.contributor.authorAltuntas, Evrim Gunes
dc.contributor.authorKilic, Pelin
dc.contributor.authorDemir-Dora, Devrim
dc.date.accessioned2026-06-27T14:46:58Z
dc.date.issued2022
dc.description.abstractMutations in the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) occur spontaneously during replication. Thousands of mutations have accumulated and continue to since the emergence of the virus. As novel mutations continue appearing at the scene, naturally, new variants are increasingly observed.Since the first occurrence of the SARS-CoV-2 infection, a wide variety of drug compounds affecting the binding sites of the virus have begun to be studied. As the drug and vaccine trials are continuing, it is of utmost importance to take into consideration the SARS-CoV-2 mutations and their respective frequencies since these data could lead the way to multi-drug combinations. The lack of effective therapeutic and preventive strategies against human coronaviruses (hCoVs) necessitates research that is of interest to the clinical applications.The reason why the mutations in glycoprotein S lead to vaccine escape is related to the location of the mutation and the affinity of the protein. At the same time, it can be said that variations should occur in areas such as the receptor-binding domain (RBD), and vaccines and antiviral drugs should be formulated by targeting more than one viral protein.en
dc.description.sponsorshipScientific and Technological Research Council of Turkey (TUuml
dc.description.sponsorshipBI?TAK) [18AG020, 2247-C]
dc.description.urihttps://doi.org/10.1016/j.cytogfr.2021.06.001
dc.identifier.doi10.1016/j.cytogfr.2021.06.001
dc.identifier.eissn1879-0305
dc.identifier.endpage22
dc.identifier.issn1359-6101
dc.identifier.pubmed34580015
dc.identifier.startpage10
dc.identifier.urihttps://hdl.handle.net/20.500.14981/64704
dc.identifier.volume63
dc.identifier.wos000767550600002
dc.language.isoeng
dc.publisherELSEVIER SCI LTD
dc.relation.ispartofCYTOKINE & GROWTH FACTOR REVIEWS
dc.rightsopenAccess
dc.subjectCOVID-19
dc.subjectMutation
dc.subjectReceptor-binding domain
dc.subjectSARS-CoV-2
dc.subjectSpike protein
dc.subjectViral variants
dc.subjectCORONAVIRUS
dc.subjectSPIKE
dc.subjectMECHANISMS
dc.subjectIDENTIFICATION
dc.subjectTRANSMISSION
dc.subjectREPLICATION
dc.subjectACE2
dc.subjectCOV
dc.subjectBiochemistry & Molecular Biology
dc.subjectCell Biology
dc.titleSARS-CoV-2 Mutations and their Viral Variants
dc.typeReview
dspace.entity.typePublication
local.import.sourceWOS

Dosyalar

Koleksiyonlar